StocksMediumUpdated•Originally published 19 October 2026•Updated 19 October 2026•
1 min read
Disc Medicine Shares Surge 60% on Successful Trial with Roche
Key Facts
1Disc Medicine announced the success of its Phase 3 APOLLO trial for bitopertin, meeting all primary and secondary endpoints.
2EyePoint failed to meet the primary endpoint of statistical non-inferiority in its Phase 3 LUCIA trial for DURAVYU.
Disc Medicine shares surged 60% following the company's announcement of the successful Phase 3 APOLLO trial for bitopertin, developed in collaboration with Roche. GlobeNewswire reported that the treatment for a rare sunlight disorder met all primary and secondary endpoints in the clinical study.
IRON closed at $56.84 on October 16, 2026, while EyePoint failed to meet the primary endpoint in its Phase 3 LUCIA trial for DURAVYU. Disc Medicine's results showed a reduction in protoporphyrin IX, whereas EyePoint's drug failed to demonstrate statistical non-inferiority in visual acuity compared to the control group despite a 38% reduction in treatment burden.